Microdosing psychedelics - Does it have an impact on emodiversity?
This observational naturalistic study (n=18) on microdosing found that it led to a decrease in positive and overall emotional diversity (emodiversity). Participants experienced more awe, wonder, or amazement and ashamed, humiliated, or disgraced emotions during microdosing days and fewer joyful, glad, or happy emotions.
Authors
- Pop, I.
- Dinkelacker, J.
Published
Abstract
Background and aims Previous research has proposed that microdosing, i.e., the repeated use of sub-threshold doses of serotonergic hallucinogens, has an impact on mood by increasing emotional awareness. We propose that increased emotional awareness could translate into higher emodiversity, a balanced experience of emotions in which emotions are experienced with more similarity in intensity and duration. We examine the effect of microdosing, the day after, as well as the cumulative effect of microdosing on overall, positive and negative emodiversity.
Methods
We use data collected over a period of 28 days sampled between February to June 2020 from 18 users that already had an active practice of microdosing at the start of the data collection. We assessed emotional states using ESM methods, i.e., signal-contingent sampling with triggers sent 5 times a day. The working dataset has a number of 224 observations days. We used mixed effects models to test our hypotheses.
Results
When taking into account the level of average affect, we found that during microdosing days positive and overall emodiversity were significantly lower. No evidence was found for a mediating role of the level of average affect. Higher cumulative instances of microdosing were not related to any of the emodiversity indexes. Participants experienced more “awe, wonder, or amazement”, “ashamed, humiliated, or disgraced” as well as less “joyful, glad, or happy” emotions during microdosing days.
Conclusion
A microdosing practice may increase the centrality of certain emotions on microdosing days, resulting in a decrease in emotional diversity.
Research Summary of 'Microdosing psychedelics - Does it have an impact on emodiversity?'
Introduction
Microdosing refers to the repeated ingestion of sub-perceptual doses of serotonergic psychedelics (for example LSD or psilocybin) with the aim of improving mood, wellbeing or cognitive function. Earlier qualitative and observational work has largely emphasised beneficial effects on mood, creativity and functioning, but quantitative and experimental studies report a fragmented and sometimes contradictory picture. Pop and colleagues argue that much prior research mixes therapeutic and enhancement aims and varies widely in design, and therefore propose emodiversity — a measure of the richness and evenness of experienced emotions — as a targeted outcome that may capture changes in emotional awareness associated with microdosing. This study sets out to test whether microdosing produces acute effects (on the day of ingestion and the day after) and cumulative effects (across repeated microdosing occasions) on overall, positive and negative emodiversity. Using repeated within-person measurement over 28 days, the researchers aim to distinguish day-level (acute) from cumulative effects and to exploit intensive sampling to better control for confounding factors. The study therefore examines whether emodiversity is higher on microdosing days and whether it increases with the number of prior microdosing days during the observation period.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- APA Citation
Pop, I., & Dinkelacker, J. (2023). Microdosing psychedelics - Does it have an impact on emodiversity?. Journal of Psychedelic Studies, 7(1), 29-35. https://doi.org/10.1556/2054.2022.00208
References (10)
Papers cited by this study that are also in Blossom
Anderson, T., Petranker, R., Christopher, A. et al. · Harm Reduction Journal (2019)
Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)
Andersson, M., Kjellgren, A. · Harm Reduction Journal (2019)
Dressler, H. M., Bright, S. J., Polito, V. · Journal of Psychedelic Studies (2021)
Van Elk, M., Fejer, G., Lempe, P. et al. · Psychopharmacology (2021)
Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · International Journal of Neuropsychopharmacology (2019)
Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Kuypers, K. P. C., Erritzoe, D., Knudsen, G. M. et al. · Journal of Psychopharmacology (2019)
Ona, G., Bouso, J. C. · Neuroscience and Biobehavioral Reviews (2020)
Cited By (2)
Papers in Blossom that reference this study
Dinkelacker, J., Pop, I. · Journal of Clinical Psychiatry (2023)
Pop, I., Dinkelacker, J. · Nordic Studies on Alcohol and Drugs (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.